Sample Page
LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE
Written by
admin
in
6. Health
Results presented at the
17th World Stroke Congress (WSC 2025)
LT3001(Odatroltide)-202 phase 2b study met primary endpoint. No symptomatic intracranial hemorrhage…
Continue Reading
←
Risk Factors for Drug-Induced Acute Generalized Exanthematous Pustulos
The Hypothalamic-Pituitary-Ovarian Axis, Ovarian Disorders, and Brain Aging
→
More posts
The Rab7-Epg5 and Rab39-ema modules cooperatively position autophagosomes for efficient lysosomal fusions
October 28, 2025
Evaluation of four insulin resistance surrogate indicators for predicting short-term mortality in critically ill patients with ischemic stroke: a nationwide retrospective cohort study | Cardiovascular Diabetology
October 28, 2025
Change to Emergency Contingency Surcharge Indian Subcontinent to North Europe & Mediterranean (E3W & E4W)
October 28, 2025
Champions League Matchday 4: Key stats and what to look out for in every game | UEFA Champions League
October 28, 2025